Share Price and Basic Stock Data
Last Updated: August 8, 2025, 5:26 pm
PEG Ratio | 0.00 |
---|
Quick Insight
Nectar Lifescience Ltd, with a current share price of ₹17.0 and a market capitalization of ₹381 Cr., reveals a low P/E ratio, standing undisclosed, indicating potential undervaluation. However, the company's ROE at 11.2% and ROCE at 5.36% signal moderate profitability and capital efficiency. With an OPM of 9.83%, Nectar faces challenges in maintaining operational margins. The company's negative net profit of -114 Cr. raises concerns about its financial health. The high promoter holding of 44.53% offers a sense of stability, although the lack of DII investment is noteworthy. Nectar's low P/BV ratio of 0.63x suggests a potential bargain for investors, yet its ICR of 1.91x may indicate some strain in meeting debt obligations. Overall, investors should closely monitor Nectar's financial performance and growth strategies to make informed decisions.
Competitors of Nectar Lifescience Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
Lactose (India) Ltd | 126 Cr. | 100 | 247/84.3 | 24.5 | 46.7 | 0.00 % | 12.9 % | 9.75 % | 10.0 |
MPS Pharmaa Ltd | 4.59 Cr. | 2.40 | 4.33/2.40 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
Gujarat Terce Laboratories Ltd | 35.2 Cr. | 47.5 | 94.9/46.3 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
Gujarat Inject (Kerala) Ltd | 30.8 Cr. | 21.0 | 29.1/13.1 | 30.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
Industry Average | 18,338.28 Cr | 1,166.98 | 48.22 | 193.59 | 0.33% | 16.63% | 15.27% | 6.18 |
Quarterly Result
Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 476 | 403 | 389 | 344 | 389 | 394 | 398 | 452 | 441 | 359 | 428 | 455 | 431 |
Expenses | 427 | 361 | 396 | 343 | 371 | 359 | 371 | 410 | 393 | 319 | 385 | 410 | 585 |
Operating Profit | 49 | 42 | -7 | 1 | 18 | 36 | 27 | 42 | 48 | 40 | 43 | 45 | -154 |
OPM % | 10% | 10% | -2% | 0% | 5% | 9% | 7% | 9% | 11% | 11% | 10% | 10% | -36% |
Other Income | 1 | 0 | 11 | 13 | 18 | 0 | 11 | 0 | 1 | 1 | 1 | 1 | 0 |
Interest | 17 | 21 | 21 | 17 | 20 | 18 | 21 | 25 | 24 | 20 | 20 | 17 | 18 |
Depreciation | 14 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 |
Profit before tax | 18 | 6 | -32 | -18 | 2 | 3 | 2 | 2 | 11 | 5 | 9 | 13 | -188 |
Tax % | 35% | 36% | -31% | -47% | -145% | 41% | 38% | 36% | 95% | 40% | 35% | 38% | -31% |
Net Profit | 12 | 4 | -22 | -9 | 4 | 2 | 1 | 2 | 1 | 3 | 6 | 8 | -130 |
EPS in Rs | 0.52 | 0.17 | -1.00 | -0.41 | 0.16 | 0.08 | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | -5.80 |
Last Updated: August 1, 2025, 4:30 pm
Below is a detailed analysis of the quarterly data for Nectar Lifescience Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 431.00 Cr.. The value appears to be declining and may need further review. It has decreased from 455.00 Cr. (Dec 2024) to 431.00 Cr., marking a decrease of 24.00 Cr..
- For Expenses, as of Mar 2025, the value is 585.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 410.00 Cr. (Dec 2024) to 585.00 Cr., marking an increase of 175.00 Cr..
- For Operating Profit, as of Mar 2025, the value is -154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 45.00 Cr. (Dec 2024) to -154.00 Cr., marking a decrease of 199.00 Cr..
- For OPM %, as of Mar 2025, the value is -36.00%. The value appears to be declining and may need further review. It has decreased from 10.00% (Dec 2024) to -36.00%, marking a decrease of 46.00%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Dec 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Mar 2025, the value is 18.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Dec 2024) to 18.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 16.00 Cr..
- For Profit before tax, as of Mar 2025, the value is -188.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Dec 2024) to -188.00 Cr., marking a decrease of 201.00 Cr..
- For Tax %, as of Mar 2025, the value is -31.00%. The value appears to be improving (decreasing) as expected. It has decreased from 38.00% (Dec 2024) to -31.00%, marking a decrease of 69.00%.
- For Net Profit, as of Mar 2025, the value is -130.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Dec 2024) to -130.00 Cr., marking a decrease of 138.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is -5.80. The value appears to be declining and may need further review. It has decreased from 0.35 (Dec 2024) to -5.80, marking a decrease of 6.15.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: July 22, 2025, 3:19 pm
Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 1,634 | 1,638 | 1,674 | 1,635 | 1,874 | 2,779 | 2,363 | 1,541 | 1,665 | 1,520 | 1,682 | 1,673 |
Expenses | 1,345 | 1,371 | 1,436 | 1,411 | 1,638 | 2,514 | 2,143 | 1,432 | 1,507 | 1,467 | 1,530 | 1,700 |
Operating Profit | 289 | 267 | 239 | 224 | 236 | 264 | 220 | 109 | 159 | 53 | 152 | -26 |
OPM % | 18% | 16% | 14% | 14% | 13% | 10% | 9% | 7% | 10% | 3% | 9% | -2% |
Other Income | 12 | 20 | 6 | 23 | 6 | 6 | 4 | -22 | 11 | 43 | 15 | 2 |
Interest | 138 | 126 | 123 | 117 | 115 | 148 | 126 | 112 | 79 | 79 | 87 | 75 |
Depreciation | 84 | 77 | 57 | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 62 |
Profit before tax | 78 | 85 | 64 | 67 | 63 | 59 | 37 | -85 | 34 | -42 | 18 | -162 |
Tax % | 21% | 22% | 15% | 18% | 17% | 19% | 15% | -14% | 26% | -43% | 73% | -30% |
Net Profit | 62 | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 5 | -114 |
EPS in Rs | 2.77 | 2.95 | 2.42 | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 |
Dividend Payout % | 4% | 3% | 4% | 2% | 2% | 2% | 4% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
---|---|---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | 6.45% | -18.18% | 1.85% | -5.45% | -7.69% | -33.33% | -328.12% | 134.25% | -196.00% | 120.83% | -2380.00% |
Change in YoY Net Profit Growth (%) | 0.00% | -24.63% | 20.03% | -7.31% | -2.24% | -25.64% | -294.79% | 462.37% | -330.25% | 316.83% | -2500.83% |
Nectar Lifescience Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | -7% |
3 Years: | 0% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -2425% |
Stock Price CAGR | |
---|---|
10 Years: | -10% |
5 Years: | -9% |
3 Years: | -17% |
1 Year: | -55% |
Return on Equity | |
---|---|
10 Years: | 0% |
5 Years: | -4% |
3 Years: | -6% |
Last Year: | -11% |
Last Updated: Unknown
Balance Sheet
Last Updated: July 25, 2025, 2:41 pm
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
Reserves | 905 | 936 | 932 | 984 | 1,036 | 1,083 | 1,114 | 1,040 | 1,065 | 1,042 | 1,047 | 934 |
Borrowings | 858 | 925 | 962 | 878 | 955 | 903 | 779 | 903 | 860 | 754 | 636 | 582 |
Other Liabilities | 609 | 628 | 640 | 696 | 710 | 696 | 718 | 423 | 443 | 371 | 486 | 509 |
Total Liabilities | 2,394 | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 |
Fixed Assets | 948 | 934 | 906 | 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | 633 |
CWIP | 122 | 91 | 99 | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 | 57 |
Investments | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
Other Assets | 1,324 | 1,485 | 1,551 | 1,597 | 1,771 | 1,780 | 1,733 | 1,517 | 1,582 | 1,449 | 1,482 | 1,357 |
Total Assets | 2,394 | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 |
Below is a detailed analysis of the balance sheet data for Nectar Lifescience Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 22.00 Cr..
- For Reserves, as of Mar 2025, the value is 934.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,047.00 Cr. (Mar 2024) to 934.00 Cr., marking a decrease of 113.00 Cr..
- For Borrowings, as of Mar 2025, the value is 582.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 636.00 Cr. (Mar 2024) to 582.00 Cr., marking a decrease of 54.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 509.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 486.00 Cr. (Mar 2024) to 509.00 Cr., marking an increase of 23.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,047.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,191.00 Cr. (Mar 2024) to 2,047.00 Cr., marking a decrease of 144.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 633.00 Cr.. The value appears to be declining and may need further review. It has decreased from 643.00 Cr. (Mar 2024) to 633.00 Cr., marking a decrease of 10.00 Cr..
- For CWIP, as of Mar 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 66.00 Cr. (Mar 2024) to 57.00 Cr., marking a decrease of 9.00 Cr..
- For Investments, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,357.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,482.00 Cr. (Mar 2024) to 1,357.00 Cr., marking a decrease of 125.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,047.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,191.00 Cr. (Mar 2024) to 2,047.00 Cr., marking a decrease of 144.00 Cr..
Notably, the Reserves (934.00 Cr.) exceed the Borrowings (582.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | -569.00 | -658.00 | -723.00 | -654.00 | -719.00 | -639.00 | -559.00 | -794.00 | -701.00 | -701.00 | -484.00 | -608.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
No data available for the Financial Efficiency data table.
This stock is not held by any mutual fund.
Key Financial Ratios
Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
---|---|---|---|---|---|
FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Basic EPS (Rs.) | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 |
Diluted EPS (Rs.) | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 |
Cash EPS (Rs.) | 2.93 | 1.56 | 3.66 | -0.58 | 4.13 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 47.68 | 47.47 | 48.51 | 47.36 | 50.66 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 47.68 | 47.47 | 48.51 | 47.36 | 50.66 |
Revenue From Operations / Share (Rs.) | 75.10 | 67.94 | 74.42 | 68.82 | 105.52 |
PBDIT / Share (Rs.) | 7.41 | 4.29 | 7.57 | 5.03 | 9.99 |
PBIT / Share (Rs.) | 4.70 | 1.65 | 5.03 | 2.34 | 7.28 |
PBT / Share (Rs.) | 0.81 | -1.89 | 1.52 | -3.78 | 1.67 |
Net Profit / Share (Rs.) | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 |
NP After MI And SOA / Share (Rs.) | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 |
PBDIT Margin (%) | 9.86 | 6.31 | 10.17 | 7.31 | 9.46 |
PBIT Margin (%) | 6.25 | 2.43 | 6.76 | 3.40 | 6.90 |
PBT Margin (%) | 1.08 | -2.78 | 2.04 | -5.49 | 1.58 |
Net Profit Margin (%) | 0.29 | -1.58 | 1.50 | -4.74 | 1.34 |
NP After MI And SOA Margin (%) | 0.29 | -1.58 | 1.50 | -4.74 | 1.34 |
Return on Networth / Equity (%) | 0.46 | -2.27 | 2.30 | -6.89 | 2.79 |
Return on Capital Employeed (%) | 8.65 | 2.85 | 8.13 | 4.09 | 11.78 |
Return On Assets (%) | 0.22 | -1.10 | 1.04 | -2.96 | 1.20 |
Long Term Debt / Equity (X) | 0.13 | 0.21 | 0.26 | 0.12 | 0.10 |
Total Debt / Equity (X) | 0.59 | 0.70 | 0.79 | 0.79 | 0.65 |
Asset Turnover Ratio (%) | 0.76 | 0.66 | 0.68 | 0.60 | 0.88 |
Current Ratio (X) | 1.50 | 1.59 | 1.56 | 1.04 | 1.29 |
Quick Ratio (X) | 0.59 | 0.62 | 0.69 | 0.54 | 0.51 |
Inventory Turnover Ratio (X) | 1.42 | 1.39 | 1.65 | 1.13 | 1.94 |
Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | -1.53 | 3.52 |
Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | -8.61 | 1.21 |
Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 101.53 | 96.48 |
Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 108.61 | 98.79 |
Interest Coverage Ratio (X) | 1.91 | 1.21 | 2.16 | 1.01 | 1.78 |
Interest Coverage Ratio (Post Tax) (X) | 1.06 | 0.69 | 1.32 | 0.57 | 1.25 |
Enterprise Value (Cr.) | 1290.98 | 1091.93 | 1381.46 | 1231.83 | 941.69 |
EV / Net Operating Revenue (X) | 0.76 | 0.71 | 0.82 | 0.79 | 0.39 |
EV / EBITDA (X) | 7.77 | 11.35 | 8.13 | 10.92 | 4.20 |
MarketCap / Net Operating Revenue (X) | 0.40 | 0.23 | 0.32 | 0.27 | 0.09 |
Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 101.53 | 96.47 |
Price / BV (X) | 0.63 | 0.33 | 0.49 | 0.39 | 0.19 |
Price / Net Operating Revenue (X) | 0.40 | 0.23 | 0.32 | 0.27 | 0.09 |
EarningsYield | 0.01 | -0.06 | 0.04 | -0.17 | 0.14 |
After reviewing the key financial ratios for Nectar Lifescience Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 5. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
- For Diluted EPS (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 5. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
- For Cash EPS (Rs.), as of Mar 24, the value is 2.93. This value is below the healthy minimum of 3. It has increased from 1.56 (Mar 23) to 2.93, marking an increase of 1.37.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 47.68. It has increased from 47.47 (Mar 23) to 47.68, marking an increase of 0.21.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 47.68. It has increased from 47.47 (Mar 23) to 47.68, marking an increase of 0.21.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 75.10. It has increased from 67.94 (Mar 23) to 75.10, marking an increase of 7.16.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 7.41. This value is within the healthy range. It has increased from 4.29 (Mar 23) to 7.41, marking an increase of 3.12.
- For PBIT / Share (Rs.), as of Mar 24, the value is 4.70. This value is within the healthy range. It has increased from 1.65 (Mar 23) to 4.70, marking an increase of 3.05.
- For PBT / Share (Rs.), as of Mar 24, the value is 0.81. This value is within the healthy range. It has increased from -1.89 (Mar 23) to 0.81, marking an increase of 2.70.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 2. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 2. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
- For PBDIT Margin (%), as of Mar 24, the value is 9.86. This value is below the healthy minimum of 10. It has increased from 6.31 (Mar 23) to 9.86, marking an increase of 3.55.
- For PBIT Margin (%), as of Mar 24, the value is 6.25. This value is below the healthy minimum of 10. It has increased from 2.43 (Mar 23) to 6.25, marking an increase of 3.82.
- For PBT Margin (%), as of Mar 24, the value is 1.08. This value is below the healthy minimum of 10. It has increased from -2.78 (Mar 23) to 1.08, marking an increase of 3.86.
- For Net Profit Margin (%), as of Mar 24, the value is 0.29. This value is below the healthy minimum of 5. It has increased from -1.58 (Mar 23) to 0.29, marking an increase of 1.87.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 0.29. This value is below the healthy minimum of 8. It has increased from -1.58 (Mar 23) to 0.29, marking an increase of 1.87.
- For Return on Networth / Equity (%), as of Mar 24, the value is 0.46. This value is below the healthy minimum of 15. It has increased from -2.27 (Mar 23) to 0.46, marking an increase of 2.73.
- For Return on Capital Employeed (%), as of Mar 24, the value is 8.65. This value is below the healthy minimum of 10. It has increased from 2.85 (Mar 23) to 8.65, marking an increase of 5.80.
- For Return On Assets (%), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 5. It has increased from -1.10 (Mar 23) to 0.22, marking an increase of 1.32.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.21 (Mar 23) to 0.13, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.59. This value is within the healthy range. It has decreased from 0.70 (Mar 23) to 0.59, marking a decrease of 0.11.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.76. It has increased from 0.66 (Mar 23) to 0.76, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 24, the value is 1.50. This value is within the healthy range. It has decreased from 1.59 (Mar 23) to 1.50, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 24, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 0.62 (Mar 23) to 0.59, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.42. This value is below the healthy minimum of 4. It has increased from 1.39 (Mar 23) to 1.42, marking an increase of 0.03.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 1.91. This value is below the healthy minimum of 3. It has increased from 1.21 (Mar 23) to 1.91, marking an increase of 0.70.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 1.06. This value is below the healthy minimum of 3. It has increased from 0.69 (Mar 23) to 1.06, marking an increase of 0.37.
- For Enterprise Value (Cr.), as of Mar 24, the value is 1,290.98. It has increased from 1,091.93 (Mar 23) to 1,290.98, marking an increase of 199.05.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.76. This value is below the healthy minimum of 1. It has increased from 0.71 (Mar 23) to 0.76, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 24, the value is 7.77. This value is within the healthy range. It has decreased from 11.35 (Mar 23) to 7.77, marking a decrease of 3.58.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.23 (Mar 23) to 0.40, marking an increase of 0.17.
- For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Price / BV (X), as of Mar 24, the value is 0.63. This value is below the healthy minimum of 1. It has increased from 0.33 (Mar 23) to 0.63, marking an increase of 0.30.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.23 (Mar 23) to 0.40, marking an increase of 0.17.
- For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 23) to 0.01, marking an increase of 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Nectar Lifescience Ltd:
- Net Profit Margin: 0.29%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.65% (Industry Average ROCE: 16.63%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.46% (Industry Average ROE: 15.27%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.06
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.59
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 48.22)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.59
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.29%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | Village Saidpura, Tehsil Derabassi, Mohali Punjab 140507 | cs@neclife.com http://www.neclife.com |
Management | |
---|---|
Name | Position Held |
Mr. Sanjiv Goyal | Chairman & Managing Director |
Mr. Puneet Sud | Director - Operations |
Dr. Indu Pal Kaur | Independent Director |
Mr. Ajay Swaroop | Independent Director |
Dr. Rupinder Tewari | Independent Director |
Dr. Kuldip Kumar Bhasin | Independent Director |
Ms. Meena Verma | Nominee Director |
FAQ
What is the intrinsic value of Nectar Lifescience Ltd?
Nectar Lifescience Ltd's intrinsic value (as of 08 August 2025) is ₹58.40 which is 317.14% higher the current market price of 14.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 314 Cr. market cap, FY2025-2026 high/low of 56.5/13.0, reserves of 934 Cr, and liabilities of 2,047 Cr.
What is the Market Cap of Nectar Lifescience Ltd?
The Market Cap of Nectar Lifescience Ltd is 314 Cr..
What is the current Stock Price of Nectar Lifescience Ltd as on 08 August 2025?
The current stock price of Nectar Lifescience Ltd as on 08 August 2025 is 14.0.
What is the High / Low of Nectar Lifescience Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Nectar Lifescience Ltd stocks is 56.5/13.0.
What is the Stock P/E of Nectar Lifescience Ltd?
The Stock P/E of Nectar Lifescience Ltd is .
What is the Book Value of Nectar Lifescience Ltd?
The Book Value of Nectar Lifescience Ltd is 42.6.
What is the Dividend Yield of Nectar Lifescience Ltd?
The Dividend Yield of Nectar Lifescience Ltd is 0.00 %.
What is the ROCE of Nectar Lifescience Ltd?
The ROCE of Nectar Lifescience Ltd is 5.36 %.
What is the ROE of Nectar Lifescience Ltd?
The ROE of Nectar Lifescience Ltd is 11.2 %.
What is the Face Value of Nectar Lifescience Ltd?
The Face Value of Nectar Lifescience Ltd is 1.00.